美諾華(603538.SH)半年度淨利潤預增54.70%-71.89%
格隆匯7月4日丨美諾華(603538.SH)公佈2022年半年度業績預增公吿,公司2022年半年度實現歸屬於母公司所有者的淨利潤預計為1.8億元到2億元,同比增長54.70%到71.89%;扣除非經常性損益事項後,歸屬於母公司所有者的淨利潤預計為1.7億元到1.9億元,同比增加73.51%到93.92%。
本期業績預增的主要原因:
(一)公司積極發展CDMO業務,加快企業升級轉型。原有在手CDMO項目陸續落地實現商業化,新客户和新項目承接有序。
(二)公司積極推進“中間體、原料藥、製劑一體化”發展戰略,深化全產業鏈垂直一體化協同,把握國家集採政策帶來的快速商業化放量機遇,公司製劑板塊持續放量,發展勢頭強勁。
(三)小核酸業務和新冠藥物中間體業務推進順利,為公司業績增長帶來新的增長點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.